186 related articles for article (PubMed ID: 28369940)
1. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Schirripa M; Zhang W; Heinemann V; Cao S; Okazaki S; Yang D; Loupakis F; Berger MD; Ning Y; Miyamoto Y; Suenaga M; Gopez RF; West JD; Hanna D; Barzi A; Falcone A; Stintzing S; Lenz HJ
Int J Cancer; 2017 Jul; 141(2):383-392. PubMed ID: 28369940
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
3. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang D; Ning Y; Matsusaka S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; West JD; Gopez R; Akihito T; Ichikawa W; Heinemann V; DePaolo RW; Lenz HJ
Int J Cancer; 2017 Sep; 141(6):1222-1230. PubMed ID: 28569041
[TBL] [Abstract][Full Text] [Related]
5. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
Winder T; Zhang W; Yang D; Ning Y; Bohanes P; Gerger A; Wilson PM; Pohl A; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2010 Nov; 16(22):5591-602. PubMed ID: 20935157
[TBL] [Abstract][Full Text] [Related]
6. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
7. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerling R; Kirchner T; Jung A; Folwaczny M; Yang D; Ning Y; Sebio A; Stremitzer S; Sunakawa Y; Matsusaka S; Yamauchi S; Loupakis F; Cremolini C; Falcone A; Lenz HJ
Mol Cancer Ther; 2015 Oct; 14(10):2374-81. PubMed ID: 26206335
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Modest DP; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Scheithauer W; Moehler M; Westphalen CB; Holch JW; von Einem JC; Held S; Heinemann V;
Eur J Cancer; 2017 Oct; 84():262-269. PubMed ID: 28843184
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
J Natl Cancer Inst; 2015 Dec; 107(12):djv258. PubMed ID: 26405092
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
15. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
[TBL] [Abstract][Full Text] [Related]
16. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
19. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
20. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F; Xu LA; Khambata-Ford S
Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
